Twist Bioscience Corp

Twist Bioscience Corp

TWST · NASDAQ · Healthcare / Biotechnology

111.60USD-2.62 (-2.29%)

Price History

Full chart

Market Stats

Previous Close114.22
Open110.50
Day Range106.81 – 114.42
52-Week Range23.30 – 219.71
Volume2.05M
Market Cap8.13B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.23
Dividend Yield0.00%
Beta2.22
50-Day Avg151.09
200-Day Avg92.13

About

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Emily Marine Leproust Ph.D.
  • Employees979
  • Headquarters681 Gateway Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.twistbioscience.com

Leadership

  • Dr. Emily Marine Leproust Ph.D.Co-Founder, Board Chair & CEO · b. 1973
  • Dr. Patrick John Finn Ph.D.President & COO · b. 1972
  • Mr. Adam LaponisChief Financial Officer · b. 1977
  • Mr. Dennis Cho J.D.Chief Legal Officer & Corporate Secretary · b. 1971
  • Ms. Paula GreenSenior Vice President of Human Resources · b. 1968
  • Mr. Robert F. WernerVP & Chief Accounting Officer · b. 1973
  • Mr. Siyuan ChenChief Technology Officer
  • Dr. Michael Fero Ph.D.Chief Information Officer
  • Dr. Colby Souders Ph.D.Chief Scientific Officer
  • Ms. Nicole MorenoSenior Vice President of Sales & Support

Financials

Income Statement

Currency: USD2016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue2.27M10.77M25.43M54.38M90.10M132.33M203.56M245.11M312.97M376.57M
Growth (%)-+374.53%+136.16%+113.89%+65.67%+46.87%+53.83%+20.41%+27.69%+20.32%
Cost of Revenue9.42M24.02M32.19M47.43M61.41M80.62M119.33M155.38M179.63M185.57M
Gross Profit-7.15M-13.25M-6.76M6.96M28.69M51.71M84.23M89.73M133.35M191.00M
Gross Margin-315.20%-123.09%-26.59%12.80%31.85%39.08%41.38%36.61%42.61%50.72%
Operating Expense36.50M45.23M63.80M115.81M168.77M204.44M333.26M306.89M354.18M327.26M
Operating Income-43.66M-58.48M-70.56M-108.85M-140.08M-152.73M-249.02M-217.16M-220.83M-136.26M
Operating Margin-1924.02%-543.16%-277.50%-200.15%-155.47%-115.41%-122.33%-88.60%-70.56%-36.18%
EBITDA-39.11M-53.10M-63.95M-99.97M-132.09M-143.91M-247.05M-174.15M-176.71M-52.10M
EBITDA Margin-1723.80%-493.21%-251.52%-183.82%-146.60%-108.75%-121.36%-71.05%-56.46%-13.83%
Net Income-44.09M-59.31M-71.24M-107.67M-139.93M-152.10M-217.86M-204.62M-208.73M-77.67M
Net Income Margin-1943.06%-550.85%-280.16%-197.98%-155.31%-114.94%-107.02%-83.48%-66.69%-20.63%
R&D18.23M19.17M20.35M35.68M43.01M69.07M120.31M106.89M90.85M80.28M
R&D as % of Total Revenue803.44%178.03%80.02%65.61%47.73%52.20%59.10%43.61%29.03%21.32%
Interest Expense746.00K905.00K1.31M1.29M787.00K367.00K80.00K5.00K29.00K-
Interest Expense % of Total Revenue32.88%8.41%5.16%2.38%0.87%0.28%0.04%0.00%0.01%-

Balance Sheet

Currency: USD2016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets76.46M85.66M115.79M186.99M398.88M702.10M961.38M776.40M614.32M641.86M
Total Liabilities153.07M219.01M317.21M34.91M62.62M121.28M171.99M152.97M141.63M168.90M
Total Equity-76.61M-133.36M-201.42M152.08M336.26M580.82M789.38M623.43M472.69M472.96M
Cash28.60M31.23M80.76M46.73M93.67M465.83M378.69M286.47M226.32M183.05M
Total Debt145.60M218.59M300.83M7.73M35.98M62.92M94.91M94.07M85.03M137.32M
Net Debt-17.41M-22.07M-71.04M-39.00M-57.69M-402.91M-283.77M-192.40M-141.29M-45.73M

Cash Flow

Currency: USD2016-09-302017-09-302018-09-302019-09-302020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow-38.59M-51.30M-66.16M-87.94M-142.25M-112.24M-124.39M-142.47M-64.09M-47.63M
Investing Cash Flow-33.34M-9.87M26.87M-104.81M-114.65M156.16M-232.93M50.61M-3.07M-24.76M
Financing Cash Flow69.65M63.80M88.82M158.58M303.73M329.18M270.53M911.00K6.89M28.54M
Capital Expenditure6.23M6.59M3.69M14.76M9.87M27.06M101.86M27.78M5.08M28.00M
Free Cash Flow-44.82M-57.90M-69.85M-102.69M-152.12M-139.31M-226.24M-170.25M-69.17M-75.63M
FCF to OCF116.14%112.85%105.57%116.78%106.94%124.11%181.89%119.50%107.92%158.80%

Earnings

Report DateAug 29, 2018Dec 19, 2018Feb 7, 2019Apr 30, 2019Aug 1, 2019Dec 11, 2019Feb 6, 2020May 7, 2020Aug 6, 2020Nov 23, 2020Feb 4, 2021May 6, 2021Aug 6, 2021Nov 22, 2021Feb 4, 2022May 5, 2022Aug 5, 2022Nov 18, 2022Feb 3, 2023May 5, 2023Aug 4, 2023Nov 17, 2023Feb 2, 2024May 2, 2024Aug 2, 2024Nov 18, 2024Feb 3, 2025May 5, 2025Aug 4, 2025Nov 14, 2025Feb 2, 2026May 4, 2026Aug 3, 2026Nov 12, 2026Nov 13, 2026
EPS Estimate0.00-0.75-0.85-0.97-0.82-0.83-0.83-0.75-0.88-0.70-0.77-0.78-0.75-0.79-1.06-1.30-1.31-1.13-1.17-1.10-1.06-0.86-0.77-0.81-0.77-0.69-0.63-0.56-0.57-0.50-0.52-0.53-0.50-0.43-0.44
EPS Actual-0.66-6.59-1.18-0.93-0.92-0.96-1.00-0.85-0.67-0.54-0.72-0.78-0.78-0.84-0.96-1.02-1.08-1.01-0.81-1.06-1.02-0.75-0.75-0.79-0.70-0.59-0.53-0.66-0.47-0.45-0.50-0.60-0.56--
Surprise--778.67%-38.82%4.12%-12.20%-15.66%-20.48%-13.33%23.86%22.86%6.49%0.00%-4.00%-6.33%9.43%21.54%17.56%10.62%30.77%3.64%3.77%12.79%2.60%2.47%9.09%14.49%15.87%-17.86%17.54%10.00%3.85%-13.21%-12.00%--
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap8.13B
Enterprise Value8.69B
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.82
Price / Book19.65
EPS-2.23
Book Value7.11
Revenue (TTM)431.80M
Gross Profit (TTM)224.38M
EBITDA-115.28M
Profit Margin-31.66%
Operating Margin-31.91%
Return on Equity-29.59%
Return on Assets-13.09%
Shares Outstanding66.30M
Shares Float61.88M
Beta2.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 13 analystsTarget 168.25
  • Strong Buy
    7
  • Buy
    2
  • Hold
    3
  • Strong Sell
    1

Ownership Breakdown

Institutions
120.76%
Insiders
0.90%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    5.83M8.80%
  • Artisan Partners Limited Partnership
    4.80M7.24%
  • FMR Inc
    4.70M7.09%
  • ARK Investment Management LLC
    4.55M6.86%
  • T. Rowe Price Associates, Inc.
    3.63M5.48%
  • State Street Corp
    3.23M4.88%
  • Vanguard Portfolio Management, LLC
    2.82M4.26%
  • Vanguard Capital Management, LLC
    2.70M4.07%
  • EdgePoint Investment
    2.52M3.80%
  • William Blair Investment Management, LLC
    2.17M3.28%
  • Farallon Capital Management, L.L.C.
    2.14M3.22%
  • Amvescap Plc.
    1.93M2.91%
  • Geode Capital Management, LLC
    1.62M2.44%
  • Thrivent Financial For Lutherans
    1.43M2.16%
  • The Goldman Sachs Group Inc
    1.41M2.12%

Top Fund Holders

  • EdgePoint Global Portfolio Series F
    2.81M4.24%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.11M3.18%
  • iShares Russell 2000 ETF
    1.68M2.53%
  • Vanguard Small Cap Index
    1.49M2.25%
  • EdgePoint Global Growth & Inc Port Sr F
    1.34M2.02%